GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovis AB (OSTO:GENO) » Definitions » Loans Receivable

Genovis AB (OSTO:GENO) Loans Receivable : kr0.0 Mil (As of Dec. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Genovis AB Loans Receivable?

Genovis AB's Loans Receivable for the quarter that ended in Dec. 2024 was kr0.0 Mil.


Genovis AB Loans Receivable Historical Data

The historical data trend for Genovis AB's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genovis AB Loans Receivable Chart

Genovis AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Genovis AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Genovis AB Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Genovis AB Loans Receivable Related Terms

Thank you for viewing the detailed overview of Genovis AB's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Genovis AB Business Description

Traded in Other Exchanges
Address
Scheelevagen 2, Box 790, Lund, SWE, SE-220 07
Genovis AB provides enzymes and technologies for the analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce, and market tools for developing new drugs and diagnostics. Its product line comprises GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company's main product category consists of Enzymes and Antibodies. Geographically its segments include Sweden and the rest of the world.

Genovis AB Headlines

No Headlines